Index
-
Market Cap
12.69B
Enterprise Value
12.22B
Income
157.02M
Sales
1.56B
Book/sh
40.18
Cash/sh
17.09
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
4700
IPO
Sep 18, 2015
P/E
81.02
Forward P/E
54.16
PEG
2.49
P/S
8.13
P/B
8.01
P/C
18.83
P/FCF
63.34
EV/EBITDA
58.38
EV/Sales
7.83
Quick Ratio
3.92
Current Ratio
5.89
Debt/Eq
0.13
LT Debt/Eq
0.12
Option/Short
Yes / Yes
EPS (ttm)
3.97
EPS next Y
5.94
EPS next Q
1.44
EPS this Y
21.28%
EPS next Y
27.60%
EPS next 5Y
21.76%
EPS past 3/5Y
- -
Sales past 3/5Y
18.33% 20.16%
EPS Y/Y TTM
-5.62%
Sales Y/Y TTM
16.98%
EPS Q/Q
-8.53%
Sales Q/Q
15.64%
Insider Own
2.87%
Insider Trans
0.00%
Inst Own
86.79%
Inst Trans
1.92%
ROA
8.33%
ROE
10.67%
ROIC
8.84%
Gross Margin
66.71%
Oper. Margin
12.13%
Profit Margin
10.06%
SMA20
-0.02%
SMA50
0.51%
SMA200
-1.35%
Trades
Shs Outstand
39.41M
Shs Float
38.28M
52W High
362.41 -11.19%
52W Low
262.94 22.41%
Volatility
0.90% 0.79%
ATR (14)
2.65
RSI (14)
51.79
Beta
0.69
Rel Volume
0.03
Avg Volume
351.41K
Volume
557
Perf Week
0.57%
Perf Month
0.28%
Perf Quarter
-1.45%
Perf Half Y
-0.29%
Perf YTD
3.52%
Perf Year
18.97%
Perf 3Y
77.39%
Perf 5Y
19.36%
Perf 10Y
409.68%
Prev Close
321.85
Price
321.86
Change %
0.00%
Analysts 14 incl. previous ratings
Rating Distribution 12 Buy · 1 Hold · 1 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Dec 18, 2025 Upgrade J JP Morgan
Neutral → Overweight $370 +15.0% Dec 11, 2025 Upgrade C Citigroup
Neutral → Buy $350 +8.7% Nov 18, 2025 Initiated W Wells Fargo
Underweight $15 -95.3% Oct 08, 2025 Upgrade N Needham
Hold → Buy $326 +1.3% Sep 02, 2025 Initiated E Evercore ISI
Outperform $300 -6.8% Mar 14, 2025 Initiated B BofA Securities
Buy $320 -0.6% Jan 21, 2025 Initiated U UBS
Buy $305 -5.2% Dec 17, 2024 Initiated O Oppenheimer
Outperform $275 -14.6% Dec 11, 2024 Upgrade W Wells Fargo
Equal Weight → Overweight $190 → $275 -14.6% Sep 18, 2024 Initiated S Stifel
Buy $238 -26.1% Sep 03, 2024 Initiated L Leerink Partners
Outperform $263 -18.3% Jul 31, 2024 Downgrade W Wells Fargo
Overweight → Equal Weight $289 → $150 -53.4% Jul 31, 2024 Downgrade C Citigroup
Buy → Neutral $165 → $178 -44.7% Feb 23, 2024 Downgrade J JP Morgan
Overweight → Neutral $284 → $250 -22.3% Sep 06, 2023 Initiated M Morgan Stanley
Equal-Weight $265 -17.7% Jul 19, 2023 Initiated R Robert W. Baird
Outperform $375 +16.5% Mar 29, 2023 Downgrade N Needham
Buy → Hold Jan 30, 2023 Initiated P Piper Sandler
Overweight $275 -14.6% Nov 04, 2022 Upgrade C Citigroup
Neutral → Buy $217 → $212 -34.1% Oct 12, 2022 Initiated J Jefferies
Buy $230 -28.5%
Show Previous Ratings
Nov-06-26 05:28PM
Oct-29-26 04:27PM
04:05PM
Oct-20-26 09:00AM
Oct-08-26 06:55AM
09:00AM
Loading…
Oct-06-26 09:00AM
Aug-14-26 05:54PM
Jul-30-26 04:43PM
04:05PM
Jul-22-26 02:35PM
Jul-07-26 09:00AM
Jun-18-26 06:00AM
Jun-17-26 07:00AM
Jun-16-26 12:27PM
Jun-15-26 09:00AM
11:34AM
Loading…
Jun-12-26 11:34AM
07:22AM
Jun-11-26 04:05PM
May-06-26 04:22PM
04:05PM
Apr-20-26 11:18AM
Apr-13-26 09:00AM
Apr-10-26 01:41PM
Apr-09-26 11:40AM
Mar-31-26 11:19AM
Mar-02-26 04:39PM
07:41AM
Feb-25-26 10:56PM
04:30PM
04:15PM
04:06PM
Loading…
04:06PM
01:29PM
(Associated Press Finance)
01:00PM
Feb-24-26 11:40AM
Feb-22-26 07:47AM
Feb-06-26 08:19AM
Feb-05-26 05:44AM
(Pharmaceutical Technology)
12:07AM
Feb-04-26 08:02AM
06:30AM
Feb-03-26 09:32PM
11:40AM
Feb-01-26 11:13PM
Jan-28-26 06:41PM
Jan-24-26 01:18AM
Jan-21-26 12:30PM
12:41AM
Jan-20-26 11:03PM
05:52AM
Jan-19-26 10:10AM
(Pharmaceutical Technology)
Jan-18-26 11:33PM
Jan-17-26 04:30AM
Jan-16-26 11:33AM
05:46AM
Jan-15-26 06:35PM
(Morningstar Research)
+11.82%
05:34PM
(The Wall Street Journal)
04:33PM
04:25PM
(The Wall Street Journal)
04:16PM
(Investor's Business Daily)
01:23PM
01:11PM
12:51PM
10:17AM
09:37AM
(The Wall Street Journal)
09:23AM
09:03AM
(Investor's Business Daily)
08:45AM
08:42AM
08:38AM
08:11AM
07:25AM
(The Wall Street Journal)
07:13AM
07:00AM
07:00AM
Jan-13-26 01:04PM
Jan-12-26 11:40AM
09:50AM
Jan-07-26 12:45PM
Dec-31-25 09:45AM
Dec-29-25 04:30PM
Dec-26-25 07:17AM
Dec-22-25 07:30AM
Dec-19-25 04:05PM
(Investor's Business Daily)
Dec-15-25 09:45AM
Dec-11-25 01:55PM
(Investor's Business Daily)
Dec-10-25 11:33PM
Dec-05-25 04:29PM
(Investor's Business Daily)
01:44PM
(Investor's Business Daily)
Dec-03-25 11:40AM
Nov-27-25 09:45AM
Nov-25-25 10:31PM
Nov-24-25 06:36PM
Nov-21-25 06:50PM
Nov-19-25 04:30PM
Nov-18-25 09:50AM
Nov-11-25 11:36PM
07:55AM
Nov-10-25 02:26PM
09:45AM
Nov-07-25 08:45AM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Grewal Harpreet Director Apr 02 '26 Sale 328.22 100 32,822 8,719 Apr 06 08:02 PM Grewal Harpreet Director Apr 02 '26 Proposed Sale 328.22 100 32,822 Apr 02 03:59 PM Yuen Maggie Chief Financial Officer Mar 02 '26 Sale 342.30 2,432 832,474 18,353 Mar 04 07:31 PM MAGGIE YUEN Officer Mar 02 '26 Proposed Sale 342.30 2,432 832,474 Mar 02 04:11 PM Grewal Harpreet Director Jan 06 '26 Sale 312.64 186 58,151 8,230 Jan 08 09:06 PM Wilder Thomas Director Jan 02 '26 Sale 310.72 186 57,794 0 Jan 06 07:33 PM Grewal Harpreet Director Jan 06 '26 Proposed Sale 312.64 186 58,151 Jan 06 03:52 PM THOMAS WILDER Director Jan 02 '26 Proposed Sale 310.72 186 57,794 Jan 02 04:02 PM Bose Arani Director Dec 11 '25 Sale 308.82 15,000 4,632,292 258,462 Dec 15 07:30 PM Roberts Johanna EVP, Gen. Counsel & Secretary Dec 05 '25 Sale 300.13 300 90,039 63,836 Dec 09 08:01 PM Roberts Johanna EVP, Gen. Counsel & Secretary Dec 01 '25 Sale 294.94 600 176,966 64,136 Dec 03 07:45 PM Grewal Harpreet Director Dec 02 '25 Sale 292.98 100 29,298 8,416 Dec 03 07:44 PM Grewal Harpreet Director Dec 02 '25 Proposed Sale 292.98 100 29,298 Dec 02 03:59 PM Roberts Johanna EVP, Gen. Counsel & Secretary Nov 25 '25 Sale 300.06 1,800 540,108 64,736 Nov 26 07:36 PM Bose Arani Director Nov 25 '25 Sale 300.19 7,500 2,251,425 275,261 Nov 26 07:36 PM Bose Arani Director Nov 21 '25 Sale 290.56 7,500 2,179,212 282,761 Nov 25 07:59 PM Johanna Roberts Officer Nov 25 '25 Proposed Sale 298.11 2,100 626,031 Nov 25 05:20 PM Arani Bose Affiliate Nov 21 '25 Proposed Sale 279.79 30,000 8,393,700 Nov 21 05:21 PM
Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.
Co-Founder Mr. Adam Elsesser J.D.
President Ms. Shruthi Narayan
Co-Founder & Director Dr. Arani Bose M.D.
Chief Financial Officer Ms. Maggie S. Yuen
Chief Accounting Officer Mr. Lambert Shiu